NGF Support Complex.

Hericenones from the fruiting body and erinacines from the mycelium have been reported to raise nerve growth factor secretion in cultured cell systems. Those are low-molecular-weight compounds that are absorbed, unlike the growth factor protein itself. The evidence sitting behind this is cell-level and animal work rather than human outcome data. A complex sold under an NGF-support name most often means this material.

Alpha-glycerophosphocholine delivers choline, and choline acetyltransferase combines choline with acetyl-CoA to make acetylcholine. Nerve growth factor signalling and cholinergic neuron function are studied together in the preclinical literature, but the substrate relationship here is straightforward biochemistry. Pairing a choline donor with a neurotrophin-support botanical stacks a substrate on a signalling rationale. No trial of the combination is cited here.

CDP-choline is hydrolysed to choline and cytidine, the cytidine converting to uridine, and both feed the Kennedy pathway that builds phosphatidylcholine for membranes. Neurite outgrowth requires new membrane, which is where the substrate argument for pairing sits. This is established biochemistry rather than a measured combination effect. The membrane-building step is a mechanism, not an outcome.

Docosahexaenoic acid is concentrated in synaptic and photoreceptor membranes and is incorporated into phospholipid at the sn-2 position. Any process that extends neurites draws on that lipid supply. Pairing a structural lipid with a signalling-oriented complex is a substrate-plus-signal rationale. It is established membrane biochemistry, not a trial result.

Serine-headgroup phospholipid supports the docking of several signalling kinases at the inner membrane face, which is part of how growth factor receptor signalling propagates. Supplemental phosphatidylserine contributes fatty acids and headgroup material after digestion rather than arriving intact. The pairing rationale is structural. No combination study is cited here.

The acetyl group carried by acetyl-L-carnitine can enter acetyl-CoA pools used both for energy and for acetylcholine synthesis. Preclinical work has also examined its relationship with neurotrophin signalling. Those are animal and cell findings, not human outcomes. It is a common companion in nerve-support formulas for that reason.

Methylcobalamin is the cofactor for methionine synthase, which regenerates methionine from homocysteine and keeps the S-adenosylmethionine pool available for methylation reactions including those in myelin lipid handling. Adequate B12 is a precondition for normal nerve maintenance regardless of what else is in a formula. This is settled cofactor biochemistry. It is a substrate-level pairing rather than a synergy in the pharmacological sense.

5-methyltetrahydrofolate donates its methyl group to cobalamin in the methionine synthase reaction, linking the two vitamins in a single cycle. A systematic review in the candidate pool examined folate supplementation in people with nerve symptoms and reported the evidence base as limited and heterogeneous. That is a review of a specific clinical population, not a general claim. The cofactor relationship itself needs no citation.

B6 in its active phosphate form is required by aromatic L-amino acid decarboxylase and by cystathionine beta-synthase. Both feed processes relevant to nerve signalling and to homocysteine handling. Very high chronic doses of pyridoxine are themselves associated with sensory nerve effects, so dose matters in both directions here. That two-sidedness is why this row is written as established pharmacology rather than as a simple benefit.

Bacoside-standardised extracts have been studied in animal models for effects on dendritic branching and on memory task performance. Those are animal outcomes and cell-level markers. The pairing with a mushroom-derived fraction stacks two preclinical rationales without a combination study behind it. Read it as formulation practice.

Curcumin has been studied for effects on neurotrophin signalling and inflammatory mediators in preclinical systems, and a 2026 review summarises that literature alongside vascular and lipid findings. Curcumin's own absorption is low without a delivery strategy, which limits how much of the cell-level chemistry applies in a person. The pairing rationale is overlapping signalling rather than a demonstrated combined effect. Nothing here is a measured combination outcome.

Nicotinamide riboside is phosphorylated to nicotinamide mononucleotide and then adenylylated to NAD, raising the cellular NAD pool. Axonal maintenance is linked to NAD handling in preclinical work through the SARM1 and NMNAT axis. Those are cell and animal findings. It is a mechanistic pairing, common in nerve-support blends.

Theanine is a glutamine analogue studied for effects on alpha wave activity and on glutamate receptor binding. It does not act on neurotrophin signalling, so the pairing is complementary rather than reinforcing. Its inclusion is a formulation convention in this category. No combination evidence is cited here.

Magnesium ions block the NMDA receptor channel in the resting state and are required as the counter-ion for ATP in hundreds of enzymatic reactions, including the kinases downstream of growth factor receptors. Adequate magnesium is a precondition rather than an added effect. This is textbook biochemistry. It supports inclusion in a nerve-support formula on substrate grounds.